SCCA2 Expressions after Treatment: Fifty-three patients were treated effectively by chemotherapy, while the 23 patients were not.
In contrast, relative SCCA2 expression rate can be used as a specific tumor marker because it was higher in the patients with lymphatic metastasis, as was lower in those with later clinical stage.
Besides being the marker of cervical squamous cell carcinoma, SCCA is also the marker of lung cancer.11-13 SCCA1 and SCCA2 are the genes coding SCCA that is intrinsically a serine protease inhibitor, and SCCA2 is located next to the gene breakpoint of 18-trisomysyndrome patients.14 The two genes, which share a homology of 92%, code neutral
Table-III: SCCA2 expression changes before and after chemotherapy.
and acid morphogenetic proteins respectively.15,16 Given that most SCCA-related studies only focused on overall SCCA genes, detecting SCCA2 may work in evaluating therapeutic effects.17 In other words, relative SCCA2 expression rate is bound to reduce after treatment, accompanied by decreased clinical stage.
SCCA2 was used instead of SCCA in practice because SCCA1 and SCCA2 function differently.
However, studies on SCCA1 and SCCA2 remain limited, especially for the debate on the correlation between SCCA and pathological parameters of cervical squamous cell carcinoma.
As a result, clarifying the effects of SCCA1 and SCCA2 on clinical detection and prognosis is particularly necessary, which requires top-notch detection techniques and large-scale studies.